The TAILOR-PCI Trial evaluates the outcomes between genotype-guided P2Y12 inhibitor selection versus conventional prescribing on ischemic outcomes. Listen to Geoff Wall and guest, Jake Galdo, discuss the role of pharmacogenomics in patient care.Additional Resource/Reference:https://jamanetwork.com/journals/jama/article-abstract/2769725 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram